🇺🇸 Xylometazoline Nasal in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Aggression — 1 report (10%)
2. Agitation — 1 report (10%)
3. Depression — 1 report (10%)
4. Drug Interaction — 1 report (10%)
5. Emotional Disorder — 1 report (10%)
6. Hypertension — 1 report (10%)
7. Irritability — 1 report (10%)
8. Off Label Use — 1 report (10%)
9. Psychomotor Hyperactivity — 1 report (10%)
10. Ventricular Tachycardia — 1 report (10%)

Source database →

Frequently asked questions

Is Xylometazoline Nasal approved in United States?

Xylometazoline Nasal does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Xylometazoline Nasal in United States?

Anabio R&D is the originator. The local marketing authorisation holder may differ — check the official source linked above.